Answers are grounded in this paper and cite their sources.
Purpose To evaluate how often studies of antibody drug conjugate-induced nausea and vomiting (ADCINV) report demographic characteristics and demographic-specific toxicity outcomes. Methods We conducted a secondary analysis of 202 studies included in a systematic review of ADCINV. We summarized study country and income setting, age and sex reporting, and whether nausea and vomiting outcomes were reported by age, sex, or country/region. Results Most studies were conducted in high-income settings (144/202, 71.3%). One hundred forty-eight studies (73.3%) reported at least one age summary, although only 22 (10.9%) reported an older-adult proportion. Overall, 123 studies (60.9%) reported the percentage of female participants. No study reported nausea or vomiting outcomes stratified by age, sex, or country/region. Conclusion ADC studies frequently report overall nausea and vomiting but do not provide the demographic-specific outcomes needed to evaluate differential risk. Standardized reporting by age, sex, and geographic setting is needed in future trials and real-world studies.
No takes yet. Share an insight, caveat, or question.
Kannout et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: